BCA
PRVB

Berman Capital Advisors’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Berman Capital Advisors’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$4K Sell
689
-181
-21% -$1.16K ﹤0.01% 1533
2021
Q2 		$7K Buy
+870
New +$7.02K ﹤0.01% 1265

Other funds holding PRVB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Berman Capital Advisors's PRVB Position: Q3 2021 in Review

Berman Capital Advisors reduced its Provention Bio, Inc. Common Stock (PRVB) stake by 21% in Q3 2021, selling an estimated $1.16K and leaving 689 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #1533.

Berman Capital Advisors first reported a position in PRVB in Q2 2021 and has held it in 2 quarters since. The position peaked at $7K in Q2 2021. 115 funds tracked by Wall St. Rank hold PRVB as of Q3 2021.

  • Berman Capital Advisors held 689 shares of Provention Bio, Inc. Common Stock worth $4K as of Q3 2021.
  • Berman Capital Advisors sold 181 Provention Bio, Inc. Common Stock shares in Q3 2021, an estimated $1.16K.
  • Provention Bio, Inc. Common Stock made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1533 holding.
  • Berman Capital Advisors first reported a position in Provention Bio, Inc. Common Stock in Q2 2021 and has held it in 2 quarters since.
  • Berman Capital Advisors's Provention Bio, Inc. Common Stock position peaked at $7K in Q2 2021.
  • 115 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.